Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial

Jessica Ailani, Richard B. Lipton, Susan Hutchinson, Kerry Knievel, Kaifeng Lu, Matthew Butler, Sung Yun Yu, Michelle Finnegan, Lawrence Severt, Joel M. Trugman

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate the long-term safety and tolerability of ubrogepant for the acute treatment of migraine. Background: Ubrogepant is an oral, calcitonin gene–related receptor antagonist in development for the acute treatment of migraine. The efficacy of ubrogepant was demonstrated in 2 phase 3 trials in which a significant improvement was observed in migraine headache pain, migraine-associated symptoms, and ability to function. Methods: This was a phase 3, multicenter, randomized, open-label, 52-week extension trial. Adults with migraine with or without aura entered the trial after completing one of 2 phase 3 lead-in trials and were re-randomized 1:1:1 to usual care, ubrogepant 50 mg, or ubrogepant 100 mg. Randomization to ubrogepant dose was blinded. Those randomized to usual care continued to treat migraine attacks with their own medication. The usual care arm was included in this trial to capture background rates of hepatic laboratory parameters and contextualize hepatic safety assessments. Safety and tolerability were the primary outcome measures. The safety population for the ubrogepant arms included all randomized participants who received at least 1 dose of treatment. All cases of alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevations of ≥3 times the upper limit of normal were adjudicated by an independent panel of liver experts who were blinded to dose. Results: The safety population included 1230 participants (404 in the ubrogepant 50-mg group, 409 in the ubrogepant 100-mg group, and 417 in the usual care group). Participants were on average 42 years of age, 90% (1106/1230) female and 85% (1043/1230) white, with an average BMI of 30 kg/m2. Throughout the trial, 21,454 migraine attacks were treated with 31,968 doses of ubrogepant. Treatment-emergent adverse events (TEAEs) were reported by 268/404 (66%) participants receiving ubrogepant 50 mg and 297/409 (73%) receiving ubrogepant 100 mg. The most commonly reported TEAE was upper respiratory tract infection (<12%); findings were similar across dose groups. Treatment-related TEAEs were reported by 42/404 (10%) participants in the ubrogepant 50-mg group and 43/409 (11%) in the ubrogepant 100-mg group. Serious adverse events (SAEs) were reported by 9/404 (2%) participants in the ubrogepant 50-mg group and 12/409 (3%) participants in the ubrogepant 100-mg group. Twenty cases of ALT/AST levels of ≥3 times the upper limit of normal were reported and reviewed by an independent clinical adjudication committee of liver experts. There were no cases of Hy’s Law. Conclusions: Long-term intermittent use of ubrogepant 50 and 100 mg given as 1 or 2 doses per attack for the acute treatment of migraine was safe and well tolerated, as indicated by a low incidence of treatment-related TEAEs and SAEs and discontinuations due to adverse events in this 1-year trial.

Original languageEnglish (US)
Pages (from-to)141-152
Number of pages12
JournalHeadache
Volume60
Issue number1
DOIs
StatePublished - Jan 1 2020

Fingerprint

Migraine Disorders
Safety
Liver
Aspartate Aminotransferases
Alanine Transaminase
Therapeutics
Calcitonin Receptors
Migraine without Aura
Migraine with Aura
Aptitude
Random Allocation
Respiratory Tract Infections
Population
Outcome Assessment (Health Care)
Pain
Incidence

Keywords

  • acute treatment
  • calcitonin gene–related peptide
  • migraine
  • safety

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine : Phase 3, Randomized, 52-Week Extension Trial. / Ailani, Jessica; Lipton, Richard B.; Hutchinson, Susan; Knievel, Kerry; Lu, Kaifeng; Butler, Matthew; Yu, Sung Yun; Finnegan, Michelle; Severt, Lawrence; Trugman, Joel M.

In: Headache, Vol. 60, No. 1, 01.01.2020, p. 141-152.

Research output: Contribution to journalArticle

Ailani, J, Lipton, RB, Hutchinson, S, Knievel, K, Lu, K, Butler, M, Yu, SY, Finnegan, M, Severt, L & Trugman, JM 2020, 'Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial', Headache, vol. 60, no. 1, pp. 141-152. https://doi.org/10.1111/head.13682
Ailani, Jessica ; Lipton, Richard B. ; Hutchinson, Susan ; Knievel, Kerry ; Lu, Kaifeng ; Butler, Matthew ; Yu, Sung Yun ; Finnegan, Michelle ; Severt, Lawrence ; Trugman, Joel M. / Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine : Phase 3, Randomized, 52-Week Extension Trial. In: Headache. 2020 ; Vol. 60, No. 1. pp. 141-152.
@article{c6d826990bdc4cf79981fc11f092e533,
title = "Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial",
abstract = "Objective: To evaluate the long-term safety and tolerability of ubrogepant for the acute treatment of migraine. Background: Ubrogepant is an oral, calcitonin gene–related receptor antagonist in development for the acute treatment of migraine. The efficacy of ubrogepant was demonstrated in 2 phase 3 trials in which a significant improvement was observed in migraine headache pain, migraine-associated symptoms, and ability to function. Methods: This was a phase 3, multicenter, randomized, open-label, 52-week extension trial. Adults with migraine with or without aura entered the trial after completing one of 2 phase 3 lead-in trials and were re-randomized 1:1:1 to usual care, ubrogepant 50 mg, or ubrogepant 100 mg. Randomization to ubrogepant dose was blinded. Those randomized to usual care continued to treat migraine attacks with their own medication. The usual care arm was included in this trial to capture background rates of hepatic laboratory parameters and contextualize hepatic safety assessments. Safety and tolerability were the primary outcome measures. The safety population for the ubrogepant arms included all randomized participants who received at least 1 dose of treatment. All cases of alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevations of ≥3 times the upper limit of normal were adjudicated by an independent panel of liver experts who were blinded to dose. Results: The safety population included 1230 participants (404 in the ubrogepant 50-mg group, 409 in the ubrogepant 100-mg group, and 417 in the usual care group). Participants were on average 42 years of age, 90{\%} (1106/1230) female and 85{\%} (1043/1230) white, with an average BMI of 30 kg/m2. Throughout the trial, 21,454 migraine attacks were treated with 31,968 doses of ubrogepant. Treatment-emergent adverse events (TEAEs) were reported by 268/404 (66{\%}) participants receiving ubrogepant 50 mg and 297/409 (73{\%}) receiving ubrogepant 100 mg. The most commonly reported TEAE was upper respiratory tract infection (<12{\%}); findings were similar across dose groups. Treatment-related TEAEs were reported by 42/404 (10{\%}) participants in the ubrogepant 50-mg group and 43/409 (11{\%}) in the ubrogepant 100-mg group. Serious adverse events (SAEs) were reported by 9/404 (2{\%}) participants in the ubrogepant 50-mg group and 12/409 (3{\%}) participants in the ubrogepant 100-mg group. Twenty cases of ALT/AST levels of ≥3 times the upper limit of normal were reported and reviewed by an independent clinical adjudication committee of liver experts. There were no cases of Hy’s Law. Conclusions: Long-term intermittent use of ubrogepant 50 and 100 mg given as 1 or 2 doses per attack for the acute treatment of migraine was safe and well tolerated, as indicated by a low incidence of treatment-related TEAEs and SAEs and discontinuations due to adverse events in this 1-year trial.",
keywords = "acute treatment, calcitonin gene–related peptide, migraine, safety",
author = "Jessica Ailani and Lipton, {Richard B.} and Susan Hutchinson and Kerry Knievel and Kaifeng Lu and Matthew Butler and Yu, {Sung Yun} and Michelle Finnegan and Lawrence Severt and Trugman, {Joel M.}",
year = "2020",
month = "1",
day = "1",
doi = "10.1111/head.13682",
language = "English (US)",
volume = "60",
pages = "141--152",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine

T2 - Phase 3, Randomized, 52-Week Extension Trial

AU - Ailani, Jessica

AU - Lipton, Richard B.

AU - Hutchinson, Susan

AU - Knievel, Kerry

AU - Lu, Kaifeng

AU - Butler, Matthew

AU - Yu, Sung Yun

AU - Finnegan, Michelle

AU - Severt, Lawrence

AU - Trugman, Joel M.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Objective: To evaluate the long-term safety and tolerability of ubrogepant for the acute treatment of migraine. Background: Ubrogepant is an oral, calcitonin gene–related receptor antagonist in development for the acute treatment of migraine. The efficacy of ubrogepant was demonstrated in 2 phase 3 trials in which a significant improvement was observed in migraine headache pain, migraine-associated symptoms, and ability to function. Methods: This was a phase 3, multicenter, randomized, open-label, 52-week extension trial. Adults with migraine with or without aura entered the trial after completing one of 2 phase 3 lead-in trials and were re-randomized 1:1:1 to usual care, ubrogepant 50 mg, or ubrogepant 100 mg. Randomization to ubrogepant dose was blinded. Those randomized to usual care continued to treat migraine attacks with their own medication. The usual care arm was included in this trial to capture background rates of hepatic laboratory parameters and contextualize hepatic safety assessments. Safety and tolerability were the primary outcome measures. The safety population for the ubrogepant arms included all randomized participants who received at least 1 dose of treatment. All cases of alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevations of ≥3 times the upper limit of normal were adjudicated by an independent panel of liver experts who were blinded to dose. Results: The safety population included 1230 participants (404 in the ubrogepant 50-mg group, 409 in the ubrogepant 100-mg group, and 417 in the usual care group). Participants were on average 42 years of age, 90% (1106/1230) female and 85% (1043/1230) white, with an average BMI of 30 kg/m2. Throughout the trial, 21,454 migraine attacks were treated with 31,968 doses of ubrogepant. Treatment-emergent adverse events (TEAEs) were reported by 268/404 (66%) participants receiving ubrogepant 50 mg and 297/409 (73%) receiving ubrogepant 100 mg. The most commonly reported TEAE was upper respiratory tract infection (<12%); findings were similar across dose groups. Treatment-related TEAEs were reported by 42/404 (10%) participants in the ubrogepant 50-mg group and 43/409 (11%) in the ubrogepant 100-mg group. Serious adverse events (SAEs) were reported by 9/404 (2%) participants in the ubrogepant 50-mg group and 12/409 (3%) participants in the ubrogepant 100-mg group. Twenty cases of ALT/AST levels of ≥3 times the upper limit of normal were reported and reviewed by an independent clinical adjudication committee of liver experts. There were no cases of Hy’s Law. Conclusions: Long-term intermittent use of ubrogepant 50 and 100 mg given as 1 or 2 doses per attack for the acute treatment of migraine was safe and well tolerated, as indicated by a low incidence of treatment-related TEAEs and SAEs and discontinuations due to adverse events in this 1-year trial.

AB - Objective: To evaluate the long-term safety and tolerability of ubrogepant for the acute treatment of migraine. Background: Ubrogepant is an oral, calcitonin gene–related receptor antagonist in development for the acute treatment of migraine. The efficacy of ubrogepant was demonstrated in 2 phase 3 trials in which a significant improvement was observed in migraine headache pain, migraine-associated symptoms, and ability to function. Methods: This was a phase 3, multicenter, randomized, open-label, 52-week extension trial. Adults with migraine with or without aura entered the trial after completing one of 2 phase 3 lead-in trials and were re-randomized 1:1:1 to usual care, ubrogepant 50 mg, or ubrogepant 100 mg. Randomization to ubrogepant dose was blinded. Those randomized to usual care continued to treat migraine attacks with their own medication. The usual care arm was included in this trial to capture background rates of hepatic laboratory parameters and contextualize hepatic safety assessments. Safety and tolerability were the primary outcome measures. The safety population for the ubrogepant arms included all randomized participants who received at least 1 dose of treatment. All cases of alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevations of ≥3 times the upper limit of normal were adjudicated by an independent panel of liver experts who were blinded to dose. Results: The safety population included 1230 participants (404 in the ubrogepant 50-mg group, 409 in the ubrogepant 100-mg group, and 417 in the usual care group). Participants were on average 42 years of age, 90% (1106/1230) female and 85% (1043/1230) white, with an average BMI of 30 kg/m2. Throughout the trial, 21,454 migraine attacks were treated with 31,968 doses of ubrogepant. Treatment-emergent adverse events (TEAEs) were reported by 268/404 (66%) participants receiving ubrogepant 50 mg and 297/409 (73%) receiving ubrogepant 100 mg. The most commonly reported TEAE was upper respiratory tract infection (<12%); findings were similar across dose groups. Treatment-related TEAEs were reported by 42/404 (10%) participants in the ubrogepant 50-mg group and 43/409 (11%) in the ubrogepant 100-mg group. Serious adverse events (SAEs) were reported by 9/404 (2%) participants in the ubrogepant 50-mg group and 12/409 (3%) participants in the ubrogepant 100-mg group. Twenty cases of ALT/AST levels of ≥3 times the upper limit of normal were reported and reviewed by an independent clinical adjudication committee of liver experts. There were no cases of Hy’s Law. Conclusions: Long-term intermittent use of ubrogepant 50 and 100 mg given as 1 or 2 doses per attack for the acute treatment of migraine was safe and well tolerated, as indicated by a low incidence of treatment-related TEAEs and SAEs and discontinuations due to adverse events in this 1-year trial.

KW - acute treatment

KW - calcitonin gene–related peptide

KW - migraine

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=85077542038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077542038&partnerID=8YFLogxK

U2 - 10.1111/head.13682

DO - 10.1111/head.13682

M3 - Article

C2 - 31913519

AN - SCOPUS:85077542038

VL - 60

SP - 141

EP - 152

JO - Headache

JF - Headache

SN - 0017-8748

IS - 1

ER -